机构:[1]Kunming Univ, Kunming Res Ctr Mol Med, Kunming 650214, Peoples R China[2]Kunming Med Univ, Affiliated Hosp 2, Dept Endocrinol, Kunming 650500, Peoples R China[3]Kunming Med Univ, Sch Pharmaceut Sci, Kunming 650500, Peoples R China[4]Kunming Med Univ, Yunnan Key Lab Pharmacol Nat Prod, Kunming 650500, Peoples R China[5]Kunming Med Univ, Affiliated Hosp 1, Dept Emergency Med, Kunming 650032, Peoples R China内科科室急诊医学科昆明医科大学附属第一医院[6]Kunming Med Univ, Affiliated Hosp 1, Intens Care Unit, Kunming 650032, Peoples R China昆明医科大学附属第一医院[7]Kunming Univ Sci & Technol, Fac Life Sci & Technol, Kunming 650500, Peoples R China
Osteoporosis is a systemic and metabolic bone disease. New drugs with good curative effect, fewer side effects, and high safety need to be developed urgently. Recently, simvastatin has been used to treat osteoporosis more frequently; however, its clinical effect and treatment mechanism are still unknown. With the use of animal models, the treatment effectiveness of simvastatin on experimental osteoporosis was investigated and the functional mechanism was preliminarily explored. The results show that simvastatin significantly increased the mechanical parameters such as maximum load, stiffness, and energy-absorbing capacity, and improved the microarchitecture. They indicated that the antiosteoporosis activity of simvastatin may be due to the promotion of proliferation and differentiation of osteoblasts. Simvastatin was effective in treating experimental osteoporosis. This study provides necessary experimental evidence for the clinical application of simvastatin in osteoporosis treatment.
基金:
National Natural Science Foundation of ChinaNational Natural Science Foundation of China [81060361]; Natural Science Foundation of Yunnan Province, ChinaNatural Science Foundation of Yunnan Province [2012FA002, 2010ZC169, 2012HB043]; Department of Education, Yunnan province, China [ZD2012006]; Natural Science Foundation of Kunming City, China [10S090202, 2012-01-01-A-R-07-0006, 2014-05-06-A-R-07-0005]
语种:
外文
被引次数:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2017]版:
大类|3 区医学
小类|4 区内分泌学与代谢4 区医学:研究与实验
最新[2023]版:
大类|3 区医学
小类|3 区医学:研究与实验4 区内分泌学与代谢
JCR分区:
出版当年[2016]版:
Q3MEDICINE, RESEARCH & EXPERIMENTALQ3ENDOCRINOLOGY & METABOLISM
最新[2023]版:
Q3MEDICINE, RESEARCH & EXPERIMENTALQ3ENDOCRINOLOGY & METABOLISM
第一作者机构:[1]Kunming Univ, Kunming Res Ctr Mol Med, Kunming 650214, Peoples R China[2]Kunming Med Univ, Affiliated Hosp 2, Dept Endocrinol, Kunming 650500, Peoples R China[3]Kunming Med Univ, Sch Pharmaceut Sci, Kunming 650500, Peoples R China[4]Kunming Med Univ, Yunnan Key Lab Pharmacol Nat Prod, Kunming 650500, Peoples R China
通讯作者:
通讯机构:[1]Kunming Univ, Kunming Res Ctr Mol Med, Kunming 650214, Peoples R China
推荐引用方式(GB/T 7714):
Dai Lifen,Xu Ming,Wu Haiying,et al.The functional mechanism of simvastatin in experimental osteoporosis[J].JOURNAL OF BONE AND MINERAL METABOLISM.2016,34(1):23-32.doi:10.1007/s00774-014-0638-y.
APA:
Dai, Lifen,Xu, Ming,Wu, Haiying,Xue, Lanjie,Yuan, Dekai...&Hu, Min.(2016).The functional mechanism of simvastatin in experimental osteoporosis.JOURNAL OF BONE AND MINERAL METABOLISM,34,(1)
MLA:
Dai, Lifen,et al."The functional mechanism of simvastatin in experimental osteoporosis".JOURNAL OF BONE AND MINERAL METABOLISM 34..1(2016):23-32